MAUNA KEA TECHNOLOGIES (FR:ALMKT)
:ALMKT
Want to see FR:ALMKT full AI Analyst Report?
Top Page
MAUNA KEA TECHNOLOGIES
(ALMKT)
Select Model
Select Model
Rating:48Neutral
Price Target:
€0.17
▲(116.25% Upside)
Action:Reiterated
Date:05/08/26
The score is held back primarily by weak financial fundamentals—persistent operating losses, continued cash burn, and negative equity—despite strong gross margins and debt reduction. Technical indicators are mixed (neutral momentum with some longer-term improvement), while the very low P/E supports valuation but is tempered by concerns about earnings quality and financial risk.
Positive Factors
High Gross Margins
A sustained ~75% gross margin implies strong unit economics for the CLE platform and probes. High product-level margins create room for scalable profitability as sales and installed base grow, supporting long-term margin recovery once operating leverage and fixed-cost absorption improve.
Negative Factors
Negative Operating Profitability & Cash Burn
Deeply negative operating margins together with persistent negative operating and free cash flow indicate the core business still consumes cash. Over months this necessitates ongoing financing, constrains reinvestment in sales and R&D, and raises execution risk for scaling the installed base.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
A sustained ~75% gross margin implies strong unit economics for the CLE platform and probes. High product-level margins create room for scalable profitability as sales and installed base grow, supporting long-term margin recovery once operating leverage and fixed-cost absorption improve.
Read all positive factors
MAUNA KEA TECHNOLOGIES (ALMKT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€33.43M
Dividend YieldN/A
Average Volume (3M)830.17K
Price to Earnings (P/E)1.2
Beta (1Y)0.93
Revenue Growth7.43%
EPS GrowthN/A
CountryFR
Employees65
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding192,097,270
10 Day Avg. Volume1,028,958
30 Day Avg. Volume830,169
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.65
Price to Sales (P/S)1.55
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€7.75M
MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model
Company Description
Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellv...
How the Company Makes Money
Mauna Kea Technologies primarily generates revenue from selling and/or leasing its endomicroscopy platform (notably its CLE systems) to hospitals and endoscopy centers, and from recurring sales of single-use or limited-use consumables associated w...
MAUNA KEA TECHNOLOGIES Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.22M | 7.66M | 11.03M | 7.48M | 7.70M |
| Gross Profit | 6.20M | 6.44M | 8.93M | 3.91M | 5.71M |
| EBITDA | -6.85M | -7.97M | -1.46M | -9.93M | -11.23M |
| Net Income | 10.77M | -10.40M | -3.73M | -11.18M | -13.45M |
Balance Sheet | |||||
| Total Assets | 13.41M | 16.25M | 22.94M | 19.79M | 24.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.97M | 1.92M | 7.91M | 3.15M | 11.89M |
| Total Debt | 12.08M | 31.93M | 29.77M | 29.20M | 28.70M |
| Total Liabilities | 18.23M | 40.63M | 40.21M | 39.72M | 35.08M |
| Stockholders Equity | -4.82M | -24.39M | -17.28M | -19.92M | -10.33M |
Cash Flow | |||||
| Free Cash Flow | -3.95M | -6.54M | -1.14M | -8.97M | -11.37M |
| Operating Cash Flow | -3.74M | -6.32M | -753.00K | -8.83M | -10.27M |
| Investing Cash Flow | -200.00K | -149.00K | -354.00K | -57.00K | -1.14M |
| Financing Cash Flow | 6.95M | 483.00K | 5.96M | 109.00K | 14.65M |
MAUNA KEA TECHNOLOGIES Technical Analysis
Negative
0.08
Price Trends
0.18
Negative
0.15
Positive
0.12
Positive
Market Momentum
>-0.01
Positive
44.05
Neutral
36.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.18, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 36.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMKT.
MAUNA KEA TECHNOLOGIES Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | €226.12M | 50.93 | 1.32% | ― | 9.08% | 21.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €45.66M | -1.03 | -14.58% | ― | 0.87% | 46.31% | |
50 Neutral | €24.95M | -5.20 | -17.18% | ― | 138.92% | 11.14% | |
48 Neutral | €33.43M | 1.19 | ― | ― | 7.43% | ― | |
48 Neutral | €206.94M | -1.75 | 59.08% | ― | 1.79% | 15.89% | |
46 Neutral | €35.67M | -2.78 | 467.60% | ― | 42.86% | 13.93% |
* General Sector Average
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.18
0.10
125.00%
FR:ALTHE
Theraclion SA
0.48
0.20
70.71%
FR:ALNOV
Novacyt
0.58
0.12
25.82%
FR:ALERS
Eurobio-Scientific SA
21.60
-3.75
-14.79%
FR:ALIKO
Ikonisys SA
1.55
-0.03
-1.90%
FR:ALMDT
Median Technologies
5.69
3.43
151.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.